| Federated learning enables big data for rare cancer boundary detection. Pati et al. Nat Commun. 2022 Dec 5;13(1):7346. doi: 10.1038/s41467-022-33407-5Federated learning enables big data for rare cancer boundary detection. Pati et al. Nat Commun. 2022 Dec 5;13(1):7346. doi: 10.1038/s41467-022-33407-5gb(51, 51, 153);">2023 Transcriptome analysis reveals tumor microenvironment changes in glioblastoma. Hoogstrate Y, Draaisma K, Ghisai SA, van Hijfte L, Barin N, de Heer I, Coppieters W, van den Bosch TPP, Bolleboom A, Gao Z, Vincent AJPE, Karim L, Deckers M, Taphoorn MJB, Kerkhof M, Weyerbrock A, Sanson M, Hoeben A, Lukacova S, Lombardi G, Leenstra S, Hanse M, Fleischeuer REM, Watts C, Angelopoulos N, Gorlia T, Golfinopoulos V, Bours V, van den Bent MJ, Robe PA, French PJ. Cancer Cell. 2023 Apr 10;41(4):678-692.e7. doi: 10.1016/j.ccell.2023.02.019. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Capper D, Reifenberger G, French PJ, Schweizer L, Weller M, Touat M, Niclou SP, Euskirchen P, Haberler C, Hegi ME, Brandner S, Le Rhun E, Rudà R, Sanson M, Tabatabai G, Sahm F, Wen PY, Wesseling P, Preusser M, van den Bent MJ. Neuro Oncol. 2023 May 4;25(5):813-826. doi: 10.1093/neuonc/noad008b(51, 51, 153) Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol. Bleeker L, Kouwenhoven MCM, de Heer I, Lissenberg-Witte BI, Gijsbers AH, Dubbink HJ, Kros JM, Gijtenbeek JMM, Kurt E, van der Rijt CCD, Swaak-Kragten AT, de Vos FY, van der Weide HL, French PJ, van den Bent MJ, Wesseling P, Bromberg JEC. J Neurooncol. 2023 Mar;162(1):225-235. doi: 10.1007/s11060-023-04285-8. IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas. van Opijnen MP, Tesileanu CMS, Dirven L, van der Meer PB, Wijnenga MMJ, Vincent AJPE, Broekman MLD, Dubbink HJ, Kros JM, van Duinen SG, Smits M, French PJ, van den Bent MJ, Taphoorn MJB, Koekkoek JAF. Neuro Oncol. 2023 Apr 6;25(4):701-709. doi: 10.1093/neuonc/noac197 2022 Alternative normalization and analysis pipeline to address systematic bias in NanoString GeoMx Digital Spatial Profiling data. van Hijfte L, Geurts M, Vallentgoed WR, Eilers PHC, Sillevis Smitt PAE, Debets R, French PJ. iScience. 2022 Dec 9;26(1):105760. doi: 10.1016/j.isci.2022.105760. The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis. Hoogstrate Y, Ghisai SA, de Wit M, de Heer I, Draaisma K, van Riet J, van de Werken HJG, Bours V, Buter J, Vanden Bempt I, Eoli M, Franceschi E, Frenel JS, Gorlia T, Hanse MC, Hoeben A, Kerkhof M, Kros JM, Leenstra S, Lombardi G, Lukacova S, Robe PA, Sepulveda JM, Taal W, Taphoorn M, Vernhout RM, Walenkamp AME, Watts C, Weller M, de Vos FYF, Jenster GW, van den Bent M, French PJ. Neuro Oncol. 2022 Mar 12;24(3):429-441. doi: 10.1093/neuonc/noab231. IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas. van Opijnen MP, Tesileanu CMS, Dirven L, van der Meer PB, Wijnenga MMJ, Vincent AJPE, Broekman MLD, Dubbink HJ, Kros JM, van Duinen SG, Smits M, French PJ, van den Bent MJ, Taphoorn MJB, Koekkoek JAF. Neuro Oncol. 2023 Apr 6;25(4):701-709. doi: 10.1093/neuonc/noac197. 3D-Engineered Scaffolds to Study Microtubes and Localization of Epidermal Growth Factor Receptor in Patient-Derived Glioma Cells. Barin N, Balcioglu HE, de Heer I, de Wit M, Lamfers MLM, van Royen ME, French PJ*, Accardo A*. Small. 2022 Oct 7:e2204485. doi: 10.1002/smll.202204485. *joint senior author Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Lassman AB, Hoang-Xuan K, Polley MC, Brandes AA, Cairncross JG, Kros JM, Ashby LS, Taphoorn MJB, Souhami L, Dinjens WNM, Laack NN, Kouwenhoven MCM, Fink KL, French PJ, Macdonald DR, Lacombe D, Won M, Gorlia T, Mehta MP, van den Bent MJ. J Clin Oncol. 2022 Aug 10;40(23):2539-2545. doi: 10.1200/JCO.21.02543 Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review. Tesileanu CMS, Vallentgoed WR, French PJ, van den Bent MJ. Eur J Cancer. 2022 Sep 21;175:214-223. doi: 10.1016/j.ejca.2022.08.016. Mitotic count is prognostic in IDH-mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trials 26053 and EORTC 22033-26033. Kros JM, Rushing E, Uwimana AL, Hernández-Laín A, Michotte A, Al-Hussaini M, Bielle F, Mawrin C, Marucci G, Tesileanu CMS, Stupp R, Baumert B, van den Bent M, French PJ, Gorlia T. Neuro Oncol. 2022 Dec 26:noac282. doi: 10.1093/neuonc/noac282. Failure of human rhombic lip differentiation underlies medulloblastoma formation. Hendrikse LD, Haldipur P, Saulnier O, Millman J, Sjoboen AH, Erickson AW, Ong W, Gordon V, Coudière-Morrison L, Mercier AL, Shokouhian M, Suárez RA, Ly M, Borlase S, Scott DS, Vladoiu MC, Farooq H, Sirbu O, Nakashima T, Nambu S, Funakoshi Y, Bahcheli A, Diaz-Mejia JJ, Golser J, Bach K, Phuong-Bao T, Skowron P, Wang EY, Kumar SA, Balin P, Visvanathan A, Lee JJY, Ayoub R, Chen X, Chen X, Mungall KL, Luu B, Bérubé P, Wang YC, Pfister SM, Kim SK, Delattre O, Bourdeaut F, Doz F, Masliah-Planchon J, Grajkowska WA, Loukides J, Dirks P, Fèvre-Montange M, Jouvet A, French PJ, Kros JM, Zitterbart K, Bailey SD, Eberhart CG, Rao AAN, Giannini C, Olson JM, Garami M, Hauser P, Phillips JJ, Ra YS, de Torres C, Mora J, Li KKW, Ng HK, Poon WS, Pollack IF, López-Aguilar E, Gillespie GY, Van Meter TE, Shofuda T, Vibhakar R, Thompson RC, Cooper MK, Rubin JB, Kumabe T, Jung S, Lach B, Lolascon A, Ferrucci V, de Antonellis P, Zollo M, Cinalli G, Robinson S, Stearns DS, Van Meir EG, Porrati P, Finocchiaro G, Massimino M, Carlotti CG, Faria CC, Roussel MF, Boop F, Chan JA, Aldinger KA, Razavi F, Silvestri E, McLendon RE, Thompson EM, Ansari M, Garre ML, Chico F, Eguía P, Pérezpeña M, Morrissy AS, Cavalli FMG, Wu X, Daniels C, Rich JN, Jones SJM, Moore RA, Marra MA, Huang X, Reimand J, Sorensen PH, Wechsler-Reya RJ, Weiss WA, Pugh TJ, Garzia L, Kleinman CL, Stein LD, Jabado N, Malkin D, Ayrault O, Golden JA, Ellison DW, Doble B, Ramaswamy V, Werbowetski-Ogilvie TE, Suzuki H, Millen KJ, Taylor MD. Nature. 2022 Sep;609(7929):1021-1028. doi: 10.1038/s41586-022-05215-w. Federated learning enables big data for rare cancer boundary detection. Pati et al. Nat Commun. 2022 Dec 5;13(1):7346. doi: 10.1038/s41467-022-33407-5. The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review. Swildens KX, Sillevis Smitt PAE, van den Bent MJ, French PJ, Geurts M. Neurooncol Adv. 2022 Jun 7;4(1):vdac087. doi: 10.1093/noajnl/vdac087 IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas. van Opijnen MP, Tesileanu CMS, Dirven L, van der Meer PB, Wijnenga MMJ, Vincent AJPE, Broekman MLD, Dubbink HJ, Kros JM, van Duinen SG, Smits M, French PJ, van den Bent MJ, Taphoorn MJB, Koekkoek JAF. Neuro Oncol. 2022 Aug 16:noac197. doi: 10.1093/neuonc/noac197 Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning. van der Voort SR, Incekara F, Wijnenga MMJ, Kapsas G, Gahrmann R, Schouten JW, Nandoe Tewarie R, Lycklama GJ, De Witt Hamer PC, Eijgelaar RS, French PJ, Dubbink HJ, Vincent AJPE, Niessen WJ, van den Bent MJ, Smits M, Klein S. Neuro Oncol. 2022 Jul 5:noac166. doi: 10.1093/neuonc/noac166 Human branching cholangiocyte organoids recapitulate functional bile duct formation. Roos FJM, van Tienderen GS, Wu H, Bordeu I, Vinke D, Albarinos LM, Monfils K, Niesten S, Smits R, Willemse J, Rosmark O, Westergren-Thorsson G, Kunz DJ, de Wit M, French PJ, Vallier L, IJzermans JNM, Bartfai R, Marks H, Simons BD, van Royen ME, Verstegen MMA, van der Laan LJW. Cell Stem Cell. 2022 May 5;29(5):776-794.e13. doi: 10.1016/j.stem.2022.04.011 Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. Draaisma K, Tesileanu CMS, de Heer I, Klein M, Smits M, Reijneveld JC, Clement PM, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Weller M, Chinot OL, Kros JM, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A, Robe PA, van den Bent MJ, French PJ. Clin Cancer Res. 2022 Jun 1;28(11):2440-2448. doi: 10.1158/1078-0432.CCR-21-3725 Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ. Clin Cancer Res. 2022 Jun 13;28(12):2527-2535. doi: 10.1158/1078-0432.CCR-21-4283 Genetic and epigenetic determinants of reactivation of Mecp2 and the inactive X chromosome in neural stem cells. Mira-Bontenbal H, Tan B, Gontan C, Goossens S, Boers RG, Boers JB, Dupont C, van Royen ME, IJcken WFJ, French P, Bedalov A, Gribnau J. Stem Cell Reports. 2022 Mar 8;17(3):693-706. doi: 10.1016/j.stemcr.2022.01.008 MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. Tesileanu CMS, Gorlia T, Golfinopoulos V, French PJ, van den Bent MJ. Neuro Oncol. 2022 Apr 1;24(4):665-667. doi: 10.1093/neuonc/noac014 Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. Snaterse G, Mies R, van Weerden WM, French PJ, Jonker JW, Houtsmuller AB, van Royen ME, Visser JA, Hofland J. Prostate Cancer Prostatic Dis. 2022 Jan 19. doi: 10.1038/s41391-022-00491-z. Online ahead of print 2021 Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas. van de Geer WS, Hoogstrate Y, Draaisma K, Robe PA, Bins S, Mathijssen RHJ, French P, van de Werken HJG, de Vos FYF. Neurooncol Adv. 2021 Nov 30;4(1):vdab177. doi: 10.1093/noajnl/vdab177. eCollection 2022 Jan-Dec. Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing. Van Hemelryk A, Mout L, Erkens-Schulze S, French PJ, van Weerden WM, van Royen ME. Biomolecules. 2021 Oct 22;11(11):1572. doi: 10.3390/biom11111572.b(51, 51, 153);">2022 The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis. Hoogstrate Y, Ghisai SA, de Wit M, de Heer I, Draaisma K, van Riet J, van de Werken HJG, Bours V, Buter J, Vanden Bempt I, Eoli M, Franceschi E, Frenel JS, Gorlia T, Hanse MC, Hoeben A, Kerkhof M, Kros JM, Leenstra S, Lombardi G, Lukacova S, Robe PA, Sepulveda JM, Taal W, Taphoorn M, Vernhout RM, Walenkamp AME, Watts C, Weller M, de Vos FYF, Jenster GW, van den Bent M, French PJ. Neuro Oncol. 2022 Mar 12;24(3):429-441. doi: 10.1093/neuonc/noab231. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. Mout L, van Royen ME, de Ridder C, Stuurman D, van de Geer WS, Marques R, Buck SAJ, French PJ, van de Werken HJG, Mathijssen RHJ, de Wit R, Lolkema MP, van Weerden WM. EBioMedicine. 2021 Nov;73:103681. doi: 10.1016/j.ebiom.2021.103681. Epub 2021 Nov 5. Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA-minus RNA sequencing data. Hoogstrate Y, Komor MA, Böttcher R, van Riet J, van de Werken HJG, van Lieshout S, Hoffmann R, van den Broek E, Bolijn AS, Dits N, Sie D, van der Meer D, Pepers F, Bangma CH, van Leenders GJLH, Smid M, French PJ, Martens JWM, van Workum W, van der Spek PJ, Janssen B, Caldenhoven E, Rausch C, de Jong M, Stubbs AP, Meijer GA, Fijneman RJA, Jenster GW. Gigascience. 2021 Dec 9;10(12):giab080. doi: 10.1093/gigascience/giab080. Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing. Van Hemelryk A, Mout L, Erkens-Schulze S, French PJ, van Weerden WM, van Royen ME. Biomolecules. 2021 Oct 22;11(11):1572. doi: 10.3390/biom11111572. Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma C. Mircea S. Tesileanu MD, Martin J. van den Bent MD, Marc Sanson MD, Wolfgang Wick MD, Alba A. Brandes MD, Paul M. Clement MD, Sara C. Erridge MD, Michael A. Vogelbaum MD, Anna K. Nowak MD, Jean F. Baurain MD, Warren P. Mason MD, Helen Wheeler MD, Olivier L. Chinot MD, Sanjeev Gill MD, Matthew Griffin MD, Leland Rogers MD, Walter Taal MD, Roberta Rudà MD, Michael Weller MD, Catherine McBain MD, Myra E. van Linde MD, Thais S. Sabedot PhD, Youri Hoogstrate PhD, Andreas von Deimling MD, Iris de Heer, Wilfred F.J. van IJcken PhD, Rutger W.W. Brouwer, Kenneth Aldape MD, Robert B. Jenkins MD, Hendrikus J. Dubbink PhD, Johan M. Kros MD, Pieter Wesseling MD, Kin Jip Cheung PhD, Vassilis Golfinopoulos MD, Brigitta G. Baumert PhD, Thierry Gorlia PhD, Houtan Noushmehr PhD, Pim J. French PhD Neuro-Oncology, 2021 Apr 29:noab088. doi: 10.1093/neuonc/noab088. non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations C Mircea S Tesileanu, Wies R Vallentgoed, Marc Sanson, Walter Taal, Paul M Clement, Wolfgang Wick, Alba Ariela Brandes, Jean Francais Baurain, Olivier L Chinot, Helen Wheeler, Sanjeev Gill, Matthew Griffin, Leland Rogers, Roberta Rudà, Michael Weller, Catherine McBain, Jaap Reijneveld, Roelien H Enting, Francesca Caparrotti, Thierry Lesimple, Susan Clenton, Anja Gijtenbeek, Elisabeth Lim, Filip de Vos, Paul J Mulholland, Martin J B Taphoorn, Iris de Heer, Youri Hoogstrate, Maurice de Wit, Lorenzo Boggiani, Sanne Venneker, Jan Oosting, Judith VMG Bovée, Sara Erridge, Michael A Vogelbaum, Anna K Nowak,,, Warren P Mason, Johan M Kros, Pieter Wesseling, Ken Aldape, Robert B Jenkins, Hendrikus J Dubbink, Brigitta Baumert,, Vassilis Golfinopoulos, Thierry Gorlia, Martin van den Bent and Pim J French Acta Neuropath. (2021) Mar 19. doi: 10.1007/s00401-021-02291-6 You spin me right ‘round Y. Hoogstrate, P.J. French Neuro-Oncology, 2021 May 5;23(5):707-708. doi: 10.1093/neuonc/noab032. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W. Nat Rev Clin Oncol. 2021 Mar;18(3):170-186. doi: 10.1038/s41571-020-00447-z. The transcriptional landscape of Shh medulloblastoma. Skowron P, Farooq H, Cavalli FMG, Morrissy AS, Ly M, Hendrikse LD, Wang EY, Djambazian H, Zhu H, Mungall KL, Trinh QM, Zheng T, Dai S, Stucklin ASG, Vladoiu MC, Fong V, Holgado BL, Nor C, Wu X, Abd-Rabbo D, Bérubé P, Wang YC, Luu B, Suarez RA, Rastan A, Gillmor AH, Lee JJY, Zhang XY, Daniels C, Dirks P, Malkin D, Bouffet E, Tabori U, Loukides J, Doz FP, Bourdeaut F, Delattre OO, Masliah-Planchon J, Ayrault O, Kim SK, Meyronet D, Grajkowska WA, Carlotti CG, de Torres C, Mora J, Eberhart CG, Van Meir EG, Kumabe T, French PJ, Kros JM, Jabado N, Lach B, Pollack IF, Hamilton RL, Rao AAN, Giannini C, Olson JM, Bognár L, Klekner A, Zitterbart K, Phillips JJ, Thompson RC, Cooper MK, Rubin JB, Liau LM, Garami M, Hauser P, Li KKW, Ng HK, Poon WS, Yancey Gillespie G, Chan JA, Jung S, McLendon RE, Thompson EM, Zagzag D, Vibhakar R, Ra YS, Garre ML, Schüller U, Shofuda T, Faria CC, López-Aguilar E, Zadeh G, Hui CC, Ramaswamy V, Bailey SD, Jones SJ, Mungall AJ, Moore RA, Calarco JA, Stein LD, Bader GD, Reimand J, Ragoussis J, Weiss WA, Marra MA, Suzuki H, Taylor MD. Nat Commun. 2021 Mar 19;12(1):1749. doi: 10.1038/s41467-021-21883-0. SMARCAD1-mediated active replication fork stability maintains genome integrity. Lo CSY, van Toorn M, Gaggioli V, Paes Dias M, Zhu Y, Manolika EM, Zhao W, van der Does M, Mukherjee C, G S C Souto Gonçalves J, van Royen ME, French PJ, Demmers J, Smal I, Lans H, Wheeler D, Jonkers J, Chaudhuri AR, Marteijn JA, Taneja N. Sci Adv. 2021 May 5;7(19):eabe7804. doi: 10.1126/sciadv.abe7804. Print 2021 May. The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma. van der Voort SR, Incekara F, Wijnenga MMJ, Kapsas G, Gahrmann R, Schouten JW, Dubbink HJ, Vincent AJPE, van den Bent MJ, French PJ, Klein S, Smits M. Data Brief. 2021 Jun 2;37:107191. doi: 10.1016/j.dib.2021.107191. eCollection 2021 Aug. Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. Gioacchino E, Koyunlar C, Zink J, de Looper H, de Jong M, Dobrzycki T, Mahony CB, Hoogenboezem R, Bosch D, van Strien PMH, van Royen ME, French PJ, Bindels E, Gussinklo KJ, Monteiro R, Touw IP, de Pater E. Blood Adv. 2021 Jul 13;5(13):2687-2700. doi: 10.1182/bloodadvances.2020002993. Subgroup and subtype-specific outcomes in adult medulloblastoma. Coltin H, Sundaresan L, Smith KS, Skowron P, Massimi L, Eberhart CG, Schreck KC, Gupta N, Weiss WA, Tirapelli D, Carlotti C, Li KKW, Ryzhova M, Golanov A, Zheludkova O, Absalyamova O, Okonechnikov K, Stichel D, von Deimling A, Giannini C, Raskin S, Van Meir EG, Chan JA, Fults D, Chambless LB, Kim SK, Vasiljevic A, Faure-Conter C, Vibhakar R, Jung S, Leary S, Mora J, McLendon RE, Pollack IF, Hauser P, Grajkowska WA, Rubin JB, van Veelen MC, French PJ, Kros JM, Liau LM, Pfister SM, Kool M, Kijima N, Taylor MD, Packer RJ, Northcott PA, Korshunov A, Ramaswamy V. Acta Neuropathol. 2021 Aug 18. doi: 10.1007/s00401-021-02358-4. Online ahead of print. Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures. Verheul C, Ntafoulis I, Kers TV, Hoogstrate Y, Mastroberardino PG, Barnhoorn S, Payán-Gómez C, Tching Chi Yen R, Struys EA, Koolen SLW, Dirven CMF, Leenstra S, French PJ, Lamfers MLM. Neurooncol Adv. 2021 Aug 2;3(1):vdab103. 2020 INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, De Vos F, Whenham N, Sanghera P, Weller M, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brilhante J, Coens C, Gorlia T, Golfinopoulos V. Neuro Oncol. 2020 May 15;22(5):684-693. doi: 10.1093/neuonc/noz222.b(51, 51, 153);">2020 Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. Weenink B, French PJ, Sillevis Smitt PAE, Debets R, Geurts M. Cancers (Basel). 2020 Mar 22;12(3):751. doi: 10.3390/cancers12030751. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W. Nat Rev Clin Oncol. 2020 Dec 8. doi: 10.1038/s41571-020-00447-z. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Tesileanu CMS, Dirven L, Wijnenga MMJ, Koekkoek JAF, Vincent AJPE, Dubbink HJ, Atmodimedjo PN, Kros JM, van Duinen SG, Smits M, Taphoorn MJB, French PJ, van den Bent MJ. Neuro Oncol. 2020 Apr 15;22(4):515-523. doi: 10.1093/neuonc/noz200. Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma. Venneker S, Kruisselbrink AB, Baranski Z, Palubeckaite I, Briaire-de Bruijn IH, Oosting J, French PJ, Danen EHJ, Bovée JVMG. Cancers (Basel). 2020 Nov 30;12(12):E3589. doi: 10.3390/cancers12123589. Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. Draaisma K, Chatzipli A, Taphoorn M, Kerkhof M, Weyerbrock A, Sanson M, Hoeben A, Lukacova S, Lombardi G, Leenstra S, Hanse M, Fleischeuer R, Watts C, McAbee J, Angelopoulos N, Gorlia T, Golfinopoulos V, Kros JM, Verhaak RGW, Bours V, van den Bent MJ, McDermott U, Robe PA, French PJ. J Clin Oncol. 2020 Jan 1;38(1):81-99. doi: 10.1200/JCO.19.00367. Epub 2019 Nov 19. Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Nobre L, Zapotocky M, Khan S, Fukuoka K, Fonseca A, McKeown T, Sumerauer D, Vicha A, Grajkowska WA, Trubicka J, Li KKW, Ng HK, Massimi L, Lee JY, Kim SK, Zelcer S, Vasiljevic A, Faure-Conter C, Hauser P, Lach B, van Veelen-Vincent ML, French PJ, Van Meir EG, Weiss WA, Gupta N, Pollack IF, Hamilton RL, Nageswara Rao AA, Giannini C, Rubin JB, Moore AS, Chambless LB, Vibhakar R, Ra YS, Massimino M, McLendon RE, Wheeler H, Zollo M, Ferruci V, Kumabe T, Faria CC, Sterba J, Jung S, López-Aguilar E, Mora J, Carlotti CG, Olson JM, Leary S, Cain J, Krskova L, Zamecnik J, Hawkins CE, Tabori U, Huang A, Bartels U, Northcott PA, Taylor MD, Yip S, Hansford JR, Bouffet E, Ramaswamy V. Cell Rep Med. 2020 Jun 23;1(3):100038. doi: 10.1016/j.xcrm.2020.100038. Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors. de Wit M, Gao Y, Mercieca D, de Heer I, Valkenburg B, van Royen ME, Aerts J, Sillevis Smitt P, French P. EBioMedicine. 2020 Jun;56:102796. doi: 10.1016/j.ebiom.2020.102796. Epub 2020 Jun 5. Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. Birzu C, French P, Caccese M, Cerretti G, Idbaih A, Zagonel V, Lombardi G. Cancers (Basel). 2020 Dec 26;13(1):47. doi: 10.3390/cancers13010047. A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma? Lombardi G, Idbaih A, Le Rhun E, Preusser M, Zagonel V, French P. Cancers (Basel). 2020 Dec 15;12(12):3775. doi: 10.3390/cancers12123775 A new carboxamide probe as On-Off fluorescent and colorimetric sensor for Fe3+ and application in detecting intracellular Fe3+ ion in living cells. Soraia Meghdadi, Niloofar Khodaverdian, Azadeh Amirnasr, Pim J. French, Martin van Royen, Erik A.C. Wiemer, Mehdi Amirnasr Journal of Photochemistry and Photobiology A: Chemistry. 2020 389:112193 Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. Amirnasr A, Verdijk RM, van Kuijk PF, Kartal P, Vriends ALM, French PJ, van Royen ME, Taal W, Sleijfer S, Wiemer EAC. Sci Rep. 2020 Feb 19;10(1):2927. doi: 10.1038/s41598-020-59789-4.
2019 Longitudinal molecular trajectories of diffuse glioma in adults. Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW; GLASS Consortium. Nature. 2019 Dec;576(7785):112-120. EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. Hoogstrate Y, Vallentgoed W, Kros JM, de Heer I, de Wit M, Eoli M, Sepulveda JM, Walenkamp AME, Frenel JS, Franceschi E, Clement PM, Weller M, van Royen ME, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, Golfinopoulos V, van den Bent M, French PJ. Neurooncol Adv. 2019 Dec 9;2(1):vdz051. doi: 10.1093/noajnl/vdz051. eCollection 2020 Jan-Dec. Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. Suzuki H, Kumar SA, Shuai S, Diaz-Navarro A, Gutierrez-Fernandez A, De Antonellis P, Cavalli FMG, Juraschka K, Farooq H, Shibahara I, Vladoiu MC, Zhang J, Abeysundara N, Przelicki D, Skowron P, Gauer N, Luu B, Daniels C, Wu X, Forget A, Momin A, Wang J, Dong W, Kim SK, Grajkowska WA, Jouvet A, Fèvre-Montange M, Garrè ML, Nageswara Rao AA, Giannini C, Kros JM, French PJ, Jabado N, Ng HK, Poon WS, Eberhart CG, Pollack IF, Olson JM, Weiss WA, Kumabe T, López-Aguilar E, Lach B, Massimino M, Van Meir EG, Rubin JB, Vibhakar R, Chambless LB, Kijima N, Klekner A, Bognár L, Chan JA, Faria CC, Ragoussis J, Pfister SM, Goldenberg A, Wechsler-Reya RJ, Bailey SD, Garzia L, Morrissy AS, Marra MA, Huang X, Malkin D, Ayrault O, Ramaswamy V, Puente XS, Calarco JA, Stein L, Taylor MD. Nature. 2019 Oct;574(7780):707-711. doi: 10.1038/s41586-019-1650-0. Epub 2019 Oct 9. Defining EGFR amplification status for clinical trial inclusion. French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M. Neuro Oncol. 2019 Oct 9;21(10):1263-1272. Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Tesileanu CMS, Dirven L, Wijnenga MMJ, Koekkoek JAF, Vincent AJPE, Dubbink HJ, Atmodimedjo PN, Kros JM, van Duinen SG, Smits M, Taphoorn MJB, French PJ, van den Bent MJ. Neuro Oncol. 2019 Oct 22 Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. Weenink B, Draaisma K, Ooi HZ, Kros JM, Sillevis Smitt PAE, Debets R, French PJ. Sci Rep. 2019 Oct 10;9(1):14643Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. Predicting the 1p/19q co-deletion status of presumed low grade glioma with an externally validated machine learning algorithm. van der Voort SR, Incekara F, Wijnenga MM, Kapsas G, Gardeniers M, Schouten JW, Starmans MP, Nandoe Tewarie R, Lycklama GJ, French PJ, Dubbink HJ, van den Bent MJ, Vincent AJ, Niessen WJ, Klein S, Smits M. Clin Cancer Res. 2019 Sep 23. pii: clincanres.1127.2019. doi: 10.1158/1078-0432.CCR-19-1127. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. Lassman AB, Aldape KD, Ansell PJ, Bain E, Curran WJ, Eoli M, French PJ, Kinoshita M, Looman J, Mehta M, Muragaki Y, Narita Y, Ocampo C, Roberts-Rapp L, Song M, Vogelbaum MA, Walenkamp AME, Wang TJC, Zhang P, van den Bent MJ. J Neurooncol. 2019 Aug;144(1):205-210. doi: 10.1007/s11060-019-03222-y. Epub 2019 Jul 4. Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients. Weenink B, van Brakel M, Wijers R, Sillevis Smitt PAE, French PJ, Debets R. J Neurooncol. 2019 Aug;144(1):79-87. doi: 10.1007/s11060-019-03228-6. Epub 2019 Jun 25 A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. Moll JM, Kumagai J, van Royen ME, Teubel WJ, van Soest RJ, French PJ, Homma Y, Jenster G, de Wit R, van Weerden WM. Prostate. 2019 Jun;79(9):937-948. doi: 10.1002/pros.23799. Epub 2019 Apr 24. Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. Amirnasr A, Verdijk RM, van Kuijk PF, Kartal P, Vriends ALM, French PJ, van Royen ME, Taal W, Sleijfer S, Wiemer EAC. Sci Rep. 2020 Feb 19;10(1):2927. doi: 10.1038/s41598-020-59789-4. 2018 Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas. Gao Y, Vallentgoed WR, French PJ. Cancers (Basel). 2018 Dec 4;10(12). pii: E489. doi: 10.3390/cancers10120489. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. Synhaeve NE, van den Bent MJ, French PJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Verdijk R, Dirven CMF, Dubbink HJ. Acta Neuropathol Commun. 2018 Nov 23;6(1):126. doi: 10.1186/s40478-018-0633-y. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A. Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13. Heterogeneity within the PF-EPN-B ependymoma subgroup. Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, McLendon RE, Lipp ES, Gururangan S, Grossbach A, French P, Kros JM, van Veelen MC, Rao AAN, Giannini C, Leary S, Jung S, Faria CC, Mora J, Schüller U, Alonso MM, Chan JA, Klekner A, Chambless LB, Hwang EI, Massimino M, Eberhart CG, Karajannis MA, Lu B, Liau LM, Zollo M, Ferrucci V, Carlotti C, Tirapelli DPC, Tabori U, Bouffet E, Ryzhova M, Ellison DW, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Pfister SM, Taylor MD, Aldape K, Pajtler KW, Kool M, Ramaswamy V. Acta Neuropathol. 2018 Aug;136(2):227-237. doi: 10.1007/s00401-018-1888-x. Epub 2018 Jul 17. Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles. González-Tablas M, Crespo I, Vital AL, Otero Á, Nieto AB, Sousa P, Patino-Alonso MC, Corchete LA, Tão H, Rebelo O, Barbosa M, Almeida MR, Guedes AF, Lopes MC, French PJ, Orfao A, Tabernero MD. Oncotarget. 2018 Jun 15;9(46):28083-28102. doi: 10.18632/oncotarget.25562. eCollection 2018 Jun 15. IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis. Gao Y, de Wit M, Struys EA, van der Linde HCZ, Salomons GS, Lamfers MLM, Willemsen R, Sillevis Smitt PAE, French PJ. PLoS One. 2018 Jun 28;13(6):e0199737. doi: 10.1371/journal.pone.0199737. eCollection 2018. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, von Deimling A. Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23. Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Fleischeuer R, Dirven CMF, Vincent AJPE, van den Bent MJ. J Neurooncol. 2018 Sep;139(2):349-357. doi: 10.1007/s11060-018-2867-8. Epub 2018 Apr 16. Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. Gao Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, Kros JM, Sillevis Smitt P, Hoang-Xuan K, Brandes AA, Vos M, Dhermain F, Enting R, Ryan GF, Chinot O, Ben Hassel M, van Linde ME, Mason WP, Gijtenbeek JMM, Balana C, von Deimling A, Gorlia T, Stupp R, Hegi ME, Baumert BG, French PJ. Eur J Cancer. 2018 May;94:168-178. doi: 10.1016/j.ejca.2018.02.023. Epub 2018 Mar 20. TRiC controls transcription resumption after UV damage by regulating Cockayne syndrome protein A. Pines A, Dijk M, Makowski M, Meulenbroek EM, Vrouwe MG, van der Weegen Y, Baltissen M, French PJ, van Royen ME, Luijsterburg MS, Mullenders LH, Vermeulen M, Vermeulen W, Pannu NS, van Attikum H. Nat Commun. 2018 Mar 12;9(1):1040. doi: 10.1038/s41467-018-03484-6. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME. Acta Neuropathol. 2018 Apr;135(4):601-615. doi: 10.1007/s00401-018-1810-6. Epub 2018 Jan 24. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Smits M, Gahrmann R, Rutten GJ, Verheul JB, Fleischeuer R, Dirven CMF, Vincent AJPE, van den Bent MJ. Neuro Oncol. 2018 Jan 10;20(1):103-112. doi: 10.1093/neuonc/nox176. Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows 2017 Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN, Kros JM, Dirven CMF, Vincent AJPE, van den Bent MJ. Acta Neuropathol. 2017 Dec;134(6):957-959. doi: 10.1007/s00401-017-1781-z The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological and molecular analysis. Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Smits M, Gahrmann R, Rutten GJ, Verheul JB, Fleischeuer R, Dirven CMF, Vincent AJPE, van den Bent MJ. Neuro Oncol. 2017 Sep 7. doi: 10.1093/neuonc/nox176. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas Lancet Oncol. 2017 Jun;18(6):e315-e329. Does early resection of presumed low-grade glioma improve survival? A clinical perspective. Wijnenga MMJ, Mattni T, French PJ, Rutten GJ, Leenstra S, Kloet F, Taphoorn MJB, van den Bent MJ, Dirven CMF, van Veelen ML, Vincent AJPE. J Neurooncol. 2017 May;133(1):137-146 Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Conter C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, López-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liau LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpeña-Diazconti M, Chico Ponce de León F, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD. Cancer Cell. 2017 Jun 12;31(6):737-754 Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection. Hou J, Brouwer WP, Kreefft K, Gama L, Price SL, Janssen HLA, French PJ, Vanwolleghem T, Boonstra A. PLoS One. 2017 Jun 29;12(6):e0179920. 2016 Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy, a report from the BELOB trial. Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, Böttcher R, Gao Y, de Wit M, Taal W, Oosterkamp HM, Walenkamp A, Beerepoot LV, Hanse MCJ, Buter J, Honkoop AH, van der Holt B, Vernhout RM, Sillevis Smitt PA, Kros JM, French PJ. Cancer Res 2016 76(3):525-34 Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AA, Giannini C, Li KK, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DC, Seow WT, Chang KT, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen ML, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJ, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DT, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD. Lancet Oncol. 2016 Apr;17(4):484-95. A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. Hayes J, Thygesen H, Gregory W, Westhead DR, French PJ, Van Den Bent MJ, Lawler SE, Short SC. Mol Oncol. 2016 Oct;10(8):1296-304. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Dubbink HJ, Atmodimedjo PN, Kros JM, French PJ, Sanson M, Idbaih A, Wesseling P, Enting R, Spliet W, Tijssen C, Dinjens WN, Gorlia T, van den Bent MJ. Neuro Oncol. 2016 Mar;18(3):388-400 2015 PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K, Wijnenga MM, Weenink B, Gao Y, Smid M, Robe P, van den Bent MJ, French PJ. Acta Neuropathol Commun. 2015 Dec 23;3(1):88. Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. Kros JM, Huizer K, Hernández-Laín A, Marucci G, Michotte A, Pollo B, Rushing EJ, Ribalta T, French P, Jaminé D, Bekka N, Lacombe D, van den Bent MJ, Gorlia T. J Clin Oncol. 2015 Apr 27 [IF 2013: 17.9] Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation Erdem-Eraslan L, Gao Y, Kloosterhof NK, Atlasi Y, Demmers J, Sacchetti A, Kros JM, Sillevis Smitt PA, Aerts J, French PJ. Eur. J. Cancer, 51(7):893-903 [IF 2013: 4.8] Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. MJ van den Bent, Y Gao, M Kerkhof, JM Kros, T Gorlia, K van Zwieten, J Prince, S van Duinen, PA Sillevis Smitt, M Taphoorn, PJ French. Neuro-Oncology,17(7):935-41 [IF 2013: 5.3] Tumor-specific mutations in low-frequency genes affect their functional properties.Erdem-Eraslan L, Heijsman D, de Wit M, Kremer A, Sacchetti A, Van der Spek P, Sillevis Smitt PAE, French PJ. J. Neuro-Oncology, 122(3):461-70. [IF 2013: 2.9] Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Dubbink HJ, Atmodimedjo PN, Kros JM, French PJ, Sanson M, Idbaih A, Wesseling P, Enting R, Spliet W, Tijssen C, Dinjens WN, Gorlia T, van den Bent MJ. Neuro Oncol. 2015 Sep 9 [IF 2013: 5.3] 2014 A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. Sun Y, Zhang W, Chen D, Lv Y, Zheng J, Lilljebjörn H, Ran L, Bao Z, Soneson C, Sjögren HO, Salford LG, Ji J, French PJ, Fioretos T, Jiang T, Fan X. Proc Natl Acad Sci U S A. 2014 Feb 18;. [IF 2013: 9.8] WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Zhukova N, Ramaswamy V, Remke M, Martin DC, Castelo-Branco P, Zhang CH, Fraser M, Tse K, Poon R, Shih D, Baskin B, Ray PN, Bouffet E, Dirks P, von Bueren AO, Pfaff E, Korshunov A, Jones D, Northcott PA, Kool M, Pugh TJ, Pomeroy SL, Cho YJ, Pietsch T, Gessi M, Rutkowski S, Bognár L, Cho BK, Eberhart CG, Conter C, Fouladi M, French PJ, Grajkowska WA, Gupta N, Hauser P, Jabado N, Vasiljevic A, Jung S, Kim SK, Klekner A, Kumabe T, Lach B, Leonard JR, Liau LM, Massimi L, Pollack IF, Ra Y, Rubin JB, Van Meir EG, Wang KC, Weiss WA, Zitterbart K, Bristow RG, Alman B, Hawkins CE, Malkin D, Clifford SC, Pfister SM, Taylor MD, Tabori U. Acta Neuropathol Commun. 2014 Dec 24;2(1):3. Cytogenetic Prognostication within Medulloblastoma Subgroups. David Shih, Paul A Northcott, Marc Remke, Andrey Korshunov, Vijay Ramaswamy, Marcel Kool, Betty Luu, Yuan Yao, Kevin Xin Wang, Adrian Dubuc, Livia Garzia, John Peacock, Stephen Mack, Xiaochong Wu, Adi Rolider, Sorana Morrissy, Florence Cavalli, David TW Jones, Karel Zitterbart, Claudia Faria, Ulrich Schüller, Leos Kren, Toshihiro Kumabe, Teiji Tominaga, Young-shin Ra, Miklos Garami, Peter Hauser, Jennifer A Chan, Shenandoah Robinson, laszlo bognar, Almos Klekner, Ali G Saad, Linda Liau, Steffen Albrecht, Adam Fontebasso, Giuseppe Cinalli, Pasqualino De Antonellis, Massimo Zollo, Michael K Cooper, Reid C Thompson, Simon Bailey, Janet C Lindsey, Concezio Di Rocco, luca massimi, Erna Michiels, Stephen W Scherer, Joanna J Phillips, Nalin Gupta, Xing Fan, Karin M Muraszko, Rajeev Vibhakar, Charles Eberhart, Maryam Fouladi, Boleslaw Lach, Shin Jung, Robert J Wechsler-Reya, Michelle Fèvre-Montange, Anne Jouvet, Nada Jabado, Ian Pollack, William A Weiss, Ji-Yeoun Lee, Byung-Kyu Cho, Seung-Ki Kim, Kyu-Chang Wang, Jeffrey Leonard, Joshua Rubin, Carmen de Torres, Cinzia Lavarino, Jaume Mora, Yoon-Jae Cho, Uri Tabori, James Olson, Amar Gajjar, Roger J Packer, Stefan Rutkowski, Scott Pomeroy, Pim French, Nanne K Kloosterhof, Johan Kros, Erwin Van Meir, Steven C Clifford, Franck Bourdeaut, Olivier Delattre, Francois Doz, Cynthia Hawkins, David Malkin, Wieslawa A Grajkowska, Marta Perek-Polnik, Eric Bouffet, James Rutka, Stefan M Pfister, and Michael D Taylor. J. Clin Oncol (2014) 32: 886-96 [IF 2013: 17.9] 2013 MGMT-STP27 methylation status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. van den Bent MJ, Erdem Eraslan L, Idbaih A, de Rooi JJ, Eilers PH, Spliet W, den Dunnen WF, Tijssen C, Wesseling P, Sillevis Smitt PA, Kros JM, Gorlia T, French PJ. Clin Cancer Res. 2013 Aug 15. [IF 2013: 8.2] Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951. Erdem-Eraslan L, Gravendeel LA, de Rooi J, Eilers PHC, Idbaih A, Spliet WGM, den Dunnen WFA, Teepen JL, Wesseling P, Sillevis Smitt PAE, Kros JM, Gorlia T, van den Bent MJ, French PJ. J. Clin Oncol (2013) 31:328-36 [IF 2013: 17.9]. Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules. Balvers RK, Kleijn A, Kloezeman JJ, French PJ, Kremer A, van den Bent MJ, Dirven CM, Leenstra S, Lamfers ML. Neuro Oncol. 2013 Sep 17 [IF 2013: 5.3] Molecular subtypes of glioma identified by genome-wide methylation profiling. Kloosterhof NK, de Rooi, JJ, Kros JM, Eilers PHC, Sillevis Smitt PAE, van den Bent MJ, FrenchPJ. Genes Chrom Cancer, 52:665-74 [IF 2013: 3.8] Structural and expression differences between the vasculature of pilocytic astrocytomas and glioblastomas. Mustafa D, Swagemakers S, French P, Luider TM, van der Spek P, Kremer A, Kros JM. J Neuropathol Exp Neurol. 2013 Dec;72(12):1171-81 [IF2013: 4.4] Raman spectroscopy can discriminate distinct glioma subtypes as defined by RNA expression profiling. Jachtenberg J-W, Bakker Schut T, French P, Kros M, Lamfers M, Leenstra S. J Raman Spectrosc (2013) 44:1217–21 [IF 2013: 2.5] Adjuvant PCV chemotherapy in newly diagnosed anaplastic oligodendroglioma – long term follow-up of EORTC Brain Tumor Group study 26951.
van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre J-Y, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K. On Behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor Group. J. Clin Oncol (2013) 31:344-50 [IF 2013: 17.9]. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, Luu B, Jones DT, Garzia L, Dubuc AM, Zhukova N, Vanner R, Kros JM, French PJ, Van Meir EG, Vibhakar R, Zitterbart K, Chan JA, Bognár L, Klekner A, Lach B, Jung S, Saad AG, Liau LM, Albrecht S, Zollo M, Cooper MK, Thompson RC, Delattre OO, Bourdeaut F, Doz FF, Garami M, Hauser P, Carlotti CG, Van Meter TE, Massimi L, Fults D, Pomeroy SL, Kumabe T, Ra YS, Leonard JR, Elbabaa SK, Mora J, Rubin JB, Cho YJ, McLendon RE, Bigner DD, Eberhart CG, Fouladi M, Wechsler-Reya RJ, Faria CC, Croul SE, Huang A, Bouffet E, Hawkins CE, Dirks PB, Weiss WA, Schüller U, Pollack IF, Rutkowski S, Meyronet D, Jouvet A, Fèvre-Montange M, Jabado N, Perek-Polnik M, Grajkowska WA, Kim SK, Rutka JT, Malkin D, Tabori U, Pfister SM, Korshunov A, von Deimling A, Taylor MD. Acta Neuropathol. 2013 Dec;126(6):917-29 [IF2013: 9.8] Subgroup Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Zhukova N, Ramaswamy V, Remke M, Shih DJH, Martin DC, Castelo-Branco P, Baskin B, Ray PN, Bouffet E, von Bueren A, Pfaff E, Korshunov A, Jones DTW, Northcott PA, Kool M, Pugh T, Pomeroy SL, Cho Y-J, Pietsch T, Gessi M, Rutkowski S, Bogntr L, Klekner A, Cho B-K, Kim S-K, Wang K-C, Eberhart CG, Fevre-Montange M, Fouladi M, French PJ, Kros M, Grajkowska WA, Gupta N, Weiss WA, Hauser P, Jabado N, Jouvet A, Jung S, Kumabe T, Lach B, Leonard JR, Rubin JB, Liau LM, Massimi L, Pollack IF, Shin Ra Y, Van Meir EG, Zitterbart K, Schüller U, Hill RM, Lindsey JC, Schwalbe EC, Bailey S, Ellison DW, Hawkins C, Malkin D, Clifford S, Pfister S, Taylor MD, Tabor U. J. Clin Oncol (2013) accepted for publication [IF 2013: 17.9] The CpG island methylator phenotype: what's in a name? Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovee JV, French PJ, van den Brandt PA, Schouten LJ, de Meyer T, Van Criekinge W, Ahuja N, Herman JG, Weijenberg MP, van Engeland M. Cancer Res. 2013 Jun 25 [IF2013: 9.3] Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors. Schaap FG, French PJ, Bovée JV. Adv Anat Pathol. 2013;20(1):32-8 [IF 2013: 3.1] 2012 Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, Dubuc A, Yao Y, Ramaswamy V, Luu B, Rolider A, Cavalli FM, Wang X, Remke M, Wu X, Chiu RY, Chu A, Chuah E, Corbett RD, Hoad GR, Jackman SD, Li Y, Lo A, Mungall KL, Nip KM, Qian JQ, Raymond AG, Thiessen NT, Varhol RJ, Birol I, Moore RA, Mungall AJ, Holt R, Kawauchi D, Roussel MF, Kool M, Jones DT, Witt H, Fernandez-L A, Kenney AM, Wechsler-Reya RJ, Dirks P, Aviv T, Grajkowska WA, Perek-Polnik M, Haberler CC, Delattre O, Reynaud SS, Doz FF, Pernet-Fattet SS, Cho BK, Kim SK, Wang KC, Scheurlen W, Eberhart CG, Fèvre-Montange M, Jouvet A, Pollack IF, Fan X, Muraszko KM, Gillespie GY, Di Rocco C, Massimi L, Michiels EM, Kloosterhof NK, French PJ, Kros JM, Olson JM, Ellenbogen RG, Zitterbart K, Kren L, Thompson RC, Cooper MK, Lach B, McLendon RE, Bigner DD, Fontebasso A, Albrecht S, Jabado N, Lindsey JC, Bailey S, Gupta N, Weiss WA, Bognár L, Klekner A, Van Meter TE, Kumabe T, Tominaga T, Elbabaa SK, Leonard JR, Rubin JB, Liau LM, Van Meir EG, Fouladi M, Nakamura H, Cinalli G, Garami M, Hauser P, Saad AG, Iolascon A, Jung S, Carlotti CG, Vibhakar R, Ra YS, Robinson S, Zollo M, Faria CC, Chan JA, Levy ML, Sorensen PH, Meyerson M, Pomeroy SL, Cho YJ, Bader GD, Tabori U, Hawkins CE, Bouffet E, Scherer SW, Rutka JT, Malkin D, Clifford SC, Jones SJ, Korbel JO, Pfister SM, Marra MA, Taylor MD. Nature (2012) 488:49-56. [IF 2012: 38.6]. Subgroup-specific alternative splicing in medulloblastoma. Dubuc AM, Morrissy AS, Kloosterhof NK, Northcott PA, Yu EP, Shih D, Peacock J, Grajkowska W, van Meter T, Eberhart CG, Pfister S, Marra MA, Weiss WA, Scherer SW, Rutka JT, French PJ, Taylor MD. Acta Neuropathol (2012) 123:485-99 [IF 2012: 9.7] 2011 Gene expression profiling of gliomas in formalin-fixed paraffin-embedded material.
Gravendeel LA, de Rooi JJ, Eilers PHC, van den Bent MJ, Sillevis Smitt PAE, French PJ. Brit J Cancer (2011), 106:538-45 [IF in 2011: 5.0] Somatic mosaic IDH1 orIDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Pansuriya, TC, van Eijk R, de Adamo P, van Ruler M, Kuijjer M, Oosting J, Cleton-Jansen A, van Oosterwijk JG, Verbeke S, Meijer D, van Wezel T, Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciot R, Limaye N, Kindblom L, Daugaard S, Godfraind C, Boon, LM, Vikkula M, Kurek KC, Szuhai K, French PJ, Bovée JVGM. Nature genetics (2011) 43:1256-61 [IF 2011: 35.5] IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Bralten LBC, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M, Leenstra S, de Jonge HR, Kros JM, Jansen EEW, Struys EA Jakobs C, Salomons GS, Diks SH, Peppelenbosch M, Kremer A, Hoogenraad CC, Sillevis Smitt PAE, French PJ. Ann Neurol (2011); 69:455-63 [IF in 2011: 11.1] A Hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Adbaih A, Sanson M, Sillevis Smitt PAE, French PJ. Clin Can Res (2011); 17:1748-55 [IF in 2011: 7.7] Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas.
Bralten LB, Nouwens S, Kockx C, Erdem L, Hoogenraad CC, Kros JM, Moorhouse MJ, Sillevis Smitt PAE, van der Spek P, van Ijcken W, Stubbs A, French PJ. Plos One (2011), 6: e22000 [IF in 2011: 4.1] Detailed characterization of alterations of chromosomes 7, 9 and 10 in glioblastomas as assessed by single nucleotide polymorphism arrays. Crespo I, Vital AL, Nieto AB, Rebelo O, Tao H, Lopes MC, Oliviera CR, French PJ, Orfao A, Tabernero MD. J Mol Diagn (2011), aug29 [IF in 2011: 3.6] Molecular subtypes of glioma. Gravendeel LA, French PJ. Chapter 3 in: Tumors of the central nervous system (Springer Book). Editor E. Hayat. Genetic Alterations in Glioma. Bralten LBC, French PJ. Cancers (2011); 3, 1129-1140 2010 The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma. Bralten LB, Gravendeel AM, Kloosterhof NK, Sacchetti A, Vrijenhoek T, Veltman JA, van den Bent MJ, Kros JM, Hoogenraad CC, Sillevis Smitt PA, French PJ. Oncogene. (2010); 29:6138-48 [IF in 2010: 7.4] Medulloblastoma comprises four distinct diseases. Norcott PA, Korshunov A, Witt H, Hielscher T, Eberhart C, Mack S, Bouffet E, Clifford S, Hawkins C, French P, Rutka J, Pfister S, Taylor MD J Clin Oncol (2010); 29:1408-14 [IF 2010: 19.0] Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, Bleeker FE, Hoogenraad CC, Michiels E, Kros JM, van den Bent M, Sillevis Smitt PA, French PJ. Human Mutation (2010); 31(3):1186-99 [IF in 2010: 6.0] IDH1 mutations: a fundamentally new understanding of diffuse glioma? Kloosterhof NK, Bralten LB, French PJ, van den Bent MJ. Lancet Oncol (2010); 12:83-91 [IF in 2010: 17.8] Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. Bralten LB, Kloosterhof NK, Gravendeel LA, Sacchetti A, Duijm EJ, Kros JM, van den Bent MJ, Hoogenraad CC, Sillevis Smitt PA, French PJ. Genes Chromosomes and Cancer (2010); 49(6):509-17 [IF in 2010: 4.0] Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Idbaih A, Dalmasso C, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, Kros JM, French PJ, Teepen J, Broët P, Delattre O, Mokhtari K, Sanson M, Delattre J-Y, van den Bent M, Hoang-Xuan K. J Neuro-Oncol, Sept 6 [IF in 2010:: 2.9] |
 |
 |